Puma Biotechnology, Inc.

NASDAQ:PBYI

Biotechnology

Healthcare
$7.22 +2.21%

+$0.16 today

Market cap
$373.26M
Beta
1.21
P/E (TTM)
15.4
EPS (TTM)
$0.48
52W Low $3.03High $7.90

Volume 0.45M

Average 0.26M

Income Statement

Follow revenue through to earnings.

Revenue

$228.37M

FY 2025 · Annual

-0.9% YoY

Operating Income

$37.30M

FY 2025 · Annual

+20.5% YoY

Net Income

$31.11M

FY 2025 · Annual

+2.8% YoY

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue253.16M228.03M235.64M230.47M228.37M
Cost of Revenue63.7M55.09M62.68M64.4M58.16M
Gross Profit189.45M172.94M172.96M166.06M170.21M
Gross Margin74.8%75.8%73.4%72.1%74.5%
Research & Development71.87M52.24M50.38M54.94M62.07M
Selling, General & Admin116.29M89.98M89.31M80.16M71.21M
Operating Expenses188.16M149.22M140.32M135.1M132.92M
Depreciation & Amortization11.31M9.84M11.52M11.52M10.94M
EBITDA(4.69M)21.89M47.52M48.08M53.34M
EBITDA Margin-1.9%9.6%20.2%20.9%23.4%
Operating Income1.29M23.72M32.64M30.97M37.3M
Operating Margin0.5%10.4%13.9%13.4%16.3%
Interest Income160K813K2.61M4.72M4.08M
Interest Expense12.81M11.59M13.33M12.45M6.62M
Other Income / Expenses(30.09M)(23.26M)(9.97M)(6.87M)(1.52M)
Income Before Tax(28.8M)457K22.67M24.1M35.78M
Pre-Tax Margin-11.4%0.2%9.6%10.5%15.7%
Income Tax Expense324K455K1.08M(6.18M)4.67M
Net Income(29.13M)2K21.59M30.28M31.11M
Net Margin-11.5%0.0%9.2%13.1%13.6%
EPS (Basic)(0.72)0.020.460.620.62
EPS (Diluted)(0.72)0.020.450.620.61
Weighted Avg Shares40.64M44.67M47.13M48.65M50.01M
Weighted Avg Shares (Diluted)40.64M44.93M47.55M49.1M50.65M

PBYI Earnings Waterfall · TTM

NASDAQ:PBYI · Revenue to Net Income

Key Ratios

EPS$0.48
Gross Margin75.1%
Net Margin9.2%
P/E Ratio-0.3
P/S Ratio4.8

Analysis

$227.2M of revenue converted into $24.4M of net income for the selected period. Gross margin is 75.1% and net margin is 9.2%, showing how much revenue survives after costs and taxes. EPS is $0.48, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 13, 2026
10-QQuarterly reportNov 9, 2026
8-KCurrent reportNov 5, 2026
SC 13D/ASC 13D/A filingOct 6, 2026
4Statement of changes in beneficial ownershipSep 16, 2026

How much revenue does PBYI generate?

Puma Biotechnology, Inc. (PBYI) reported $228.37M of revenue in fiscal 2025.

Is PBYI profitable?

Puma Biotechnology, Inc. (PBYI) reported $31.11M of net income, with a net margin of 13.6%.